Immunocore (NASDAQ:IMCR) Stock Gets Price Target Trim from HC Wainwright

by · The Cerbat Gem

Immunocore (NASDAQ:IMCR – Free Report) had its target price decreased by HC Wainwright from $100.00 to $80.00 in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunocore’s Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.26) EPS, Q1 2027 earnings at $0.17 EPS, Q2 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.52 EPS, FY2027 earnings at $1.34 EPS, FY2028 earnings at $1.81 EPS, FY2029 earnings at $4.15 EPS and FY2030 earnings at $6.98 EPS.

A number of other research firms have also recently weighed in on IMCR. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 target price for the company. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Read Our Latest Analysis on IMCR

Immunocore Stock Performance

NASDAQ IMCR opened at $30.48 on Tuesday. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -46.89 and a beta of 0.82. The stock has a 50-day moving average of $31.22 and a 200 day moving average of $31.66. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. The business had revenue of $102.22 million for the quarter, compared to analyst estimates of $152.09 million. Sell-side analysts anticipate that Immunocore will post -0.20 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in Immunocore by 30.9% during the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after acquiring an additional 140,308 shares during the last quarter. Braidwell LP acquired a new position in shares of Immunocore during the 2nd quarter worth approximately $16,552,000. Renaissance Technologies LLC grew its position in shares of Immunocore by 16.4% in the first quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock valued at $4,945,000 after purchasing an additional 23,100 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Immunocore in the second quarter valued at approximately $2,145,000. Finally, Alps Advisors Inc. grew its position in shares of Immunocore by 32.7% in the third quarter. Alps Advisors Inc. now owns 68,246 shares of the company’s stock valued at $2,067,000 after purchasing an additional 16,826 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Top Immunocore Stories

Investors following IMCR have been watching these stories:

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Further Reading